ReviewInternational journal of nanomedicine2026
Current Perspectives on Radiosensitizers in Cancer Radiotherapy.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This review analyzes the multifactorial mechanisms of tumor radioresistance and evaluates the current landscape of innovative strategies to overcome this limitation, thereby improving the efficacy of radiotherapy. Methods: We evaluated the key molecular and cellular drivers contributing to radioresistance. A comprehensive evaluation of contemporary radiosensitization strategies was then undertaken, with particular focus on nanomaterials (the predominant class discussed) while also covering nanomaterials, natural bioactive compounds, targeted molecular inhibitors, immunomodulators, and nucleic acid therapies. Each class of agents was subjected to a critical analysis spanning from mechanistic insights and supportive preclinical data to progress in clinical translation. Findings from foundational in vitro research, in vivo models, and preliminary clinical studies were consolidated to form a cohesive perspective. Results: Tumor radioresistance is mediated by dynamic interactions between intrinsic cellular properties and the tumor microenvironment. Recent strategies have demonstrated potential through physical dose enhancement, multi‑target modulation, precise interference with DNA damage repair and cell‑cycle regulation, and combinatorial immunoradiotherapy. These approaches collectively enable selective tumor radiosensitization while modulating key resistance pathways. Conclusion: Despite considerable preclinical promise, clinical adoption faces challenges including biological heterogeneity, suboptimal agent delivery, normal tissue toxicity, and a lack of validated predictive biomarkers. Future advances will rely on the development of intelligent multifunctional platforms, biomarker‑guided patient stratification, and rationally designed combination therapies to achieve durable therapeutic gains.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.